Details for New Drug Application (NDA): 220305
The generic ingredient in KOMZIFTI is ziftomenib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ziftomenib profile page.
Summary for 220305
| Tradename: | KOMZIFTI |
| Applicant: | Kura |
| Ingredient: | ziftomenib |
| Patents: | 8 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 220305
Generic Entry Date for 220305*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 220305
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| KOMZIFTI | ziftomenib | CAPSULE;ORAL | 220305 | NDA | Kura Oncology, Inc. | 84696-200 | 84696-200-90 | 90 CAPSULE in 1 BOTTLE (84696-200-90) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 200MG | ||||
| Approval Date: | Nov 13, 2025 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Nov 13, 2030 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | 10,077,271 | Patent Expiration: | Mar 16, 2036 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | 10,174,041 | Patent Expiration: | Mar 16, 2036 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF INHIBITING MENIN INTERACTION | ||||||||
Complete Access Available with Subscription
